Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Colorcon
Medtronic
Boehringer Ingelheim
Dow

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Litigation Details for Massachusetts Institute of Technology v. Imclone Systems, Incorporated (D. Mass. 2004)

See Plans and Pricing

« Back to Dashboard

Biologic Drugs cited in Massachusetts Institute of Technology v. Imclone Systems, Incorporated
The biologic drug covered by the patent cited in this case is   Start Trial .

Details for Massachusetts Institute of Technology v. Imclone Systems, Incorporated (D. Mass. 2004)

Date Filed Document No. Description Snippet Link To Document
2006-07-28 143 Memorandum & ORDER lucrative cancer-fighting drug, violates U.S. Patent No. 4,663,281, “Enhanced Production of Proteinaceous Materials…Eucaryotic Cells” (the ‘281 patent). The ‘281 patent was issued to MIT by the U.S. Patent and Trade Office on …case law. The doctrine of patent exhaustion is almost as old as the patent system itself and is based…from the buyer by virtue of a patent. The exercise for a court in a patent exhaustion case is fairly straightforward…its rights under the patent and, if it did, was any residual interest in the patent retained? “As a general External link to document
2007-06-08 173 Findings of Fact & Conclusions of Law treatment drug, infringes MIT’s U.S. Patent No. 4,663,281 (the ‘281 patent), titled “Enhanced Production of…subject of the Gillies’ patent. (Damon no longer exists and the subject patent is now owned by Repligen…the subject patent expired in May 2004 (and Repligen sued us one day before this patent expired).…Repligen Corporation (collectively MIT), brought this patent infringement lawsuit against ImClone Systems, …Proteinaceous Materials in Eucaryotic Cells.” The ‘281 patent asserts ownership of an antibody styled as the External link to document
2007-07-02 181 Motion for Miscellaneous Relief infringes several claims of U.S. Patent No. 4,663,281 (the ‘281 patent). Infringement is a “two-step inquiry…the meaning of patent claims. The meaning of claim terms is the central issue of patent litigation. With…Fed. Cir. 2005) . The asserted claims of the ‘281 patent contain a number of disputed claim terms that …present in all of the asserted claims of the ‘281 patent and whose construction could be case dispositive… 4 of 12 the art in the context of the ‘281 patent specification is disputed between the parties and External link to document
2007-07-23 199 Motion to Seal Document Validity of United States Patent Number 4,663,281. 4. Exhibit J to External link to document
2007-07-23 203 Exhibit J STRUHL RE VALIDITY OF UNITED STATES PATENT NUMBER 4,663,281 Case 1:04-cv-10884-RGS …KEVIN STRUHL RE VALIDITY OF UNITED STATES PATENT NUMBER 4,663,281 Case 1:04-cv-10884-RGS Document…#39;281 patent Dr. Aaronson claims that the prosecution history of the '28 1 patent confirms…the claims and the specification of the '281 patent. Under Dr. Aaronson7sdefinition of "portion… sequence set forth in Figure 10. (The '281 patent, at 756-10:40.) The specification also teaches External link to document
2007-07-23 204 Declaration a true and correct copy of United States Patent No. 4,663,281. 3. Exhibit B is a true and…Kevin Struhl Re: Validity of United States Patent Number 4,663,281. Exhibit I has been filed under seal, …Edmund Pitcher, the patent attorney prosecuting the application leading to the ‘281 patent. 4. …issued by the U.S. Patent & Trademark Office during the prosecution of the ‘281 patent, rejecting the…December 15, 1986 Notice of Allowance of the ‘281 patent. 5. Exhibit D is a true and correct External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
Baxter
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.